Curis to Present at the BioCentury Future Leaders in the Biotech Industry Conference

Curis to Present at the BioCentury Future Leaders in the Biotech Industry
Conference

LEXINGTON, Mass., March 29, 2013 (GLOBE NEWSWIRE) -- Curis, Inc.
(Nasdaq:CRIS), an oncology-focused company seeking to develop next generation
targeted drug candidates for cancer treatment, today announced that the
Company will be presenting at the BioCentury Future Leaders in the Biotech
Industry Conference at 11:30 a.m. ET on April 5, 2013, in New York City.

Dan Passeri, Chief Executive Officer, will provide an overview of Erivedge®
(vismodegib), a hedgehog pathway inhibitor under collaboration with Genentech
that is the first FDA-approved medicine for people with advanced forms of
basal cell carcinoma. Mr. Passeri will also provide an overview of Curis'
other cancer programs including CUDC-427, CUDC-907, as well as discuss other
corporate activities.

A corresponding webcast of the presentation can be accessed by visiting:

http://www.media-server.com/m/p/ugxhv6ah

The presentation will be archived shortly after the live event and available
for 30 days following the conference. In addition, it will be available for 30
days on the Investor Relations section of the Curis website at www.curis.com.

About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop and
commercialize next generation targeted small molecule drug candidates for
cancer treatment. Erivedge® is the first and only FDA-approved medicine for
the treatment of advanced basal cell carcinoma and is being commercialized and
developed by Roche and Genentech, a member of the Roche Group, under a
collaboration agreement between Curis and Genentech. Curis is also leveraging
its experience in targeting signaling pathways to develop proprietary targeted
cancer programs, including CUDC-427, a small molecule antagonist of IAP
proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information,
visit Curis' website at www.curis.com.

CONTACT: For More Information:
         Michael P. Gray
         Chief Financial Officer
         Curis, Inc.
         617-503-6632
         mgray@curis.com

Curis, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.